RxDoctor Payments Data

Lisa Simonian

Nurse Practitioner · Erie, PANPI 1124027339

Payments from drug & device makers

$545in general payments, 2019–2025

Across 27 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$140
  • Harmony Biosciences LLC$80
  • Takeda Pharmaceuticals U.S.A., Inc.$61
  • Philips North America LLC$55
  • Grifols USA, LLC$35
  • Boehringer Ingelheim$35
  • plus $138 from 7 others

What the payments were for

  • Food & beverage$46585%
  • Education$8015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$545 in reported general payments places this provider in the 75th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$15,575
Medicare patients
92
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter153$104,252
Breo ElliptaFluticasone/Vilanterol60$27,426
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$20,471
Spiriva RespimatTiotropium Bromide33$16,720
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$12,584
Incruse ElliptaUmeclidinium Bromide27$9,517
Fluticasone-SalmeterolFluticasone Propion/Salmeterol87$9,205
Arnuity ElliptaFluticasone Furoate27$8,671
Advair HfaFluticasone Propion/Salmeterol19$6,876
DuleraMometasone/Formoterol20$6,723
Albuterol Sulfate HfaAlbuterol Sulfate164$4,752
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$3,507
Wixela InhubFluticasone Propion/Salmeterol18$3,468
Roflumilast20$3,408
BreynaBudesonide/Formoterol Fumarate17$2,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$18$162,449284 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$35$37,19171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →